

Primatene® Mist (epinephrine) – New over-the-counter drug (OTC) approval

- On November 8, 2018, the <u>FDA announced</u> the <u>approval</u> of <u>Amphastar Pharmaceuticals' Primatene</u>
 <u>Mist (epinephrine)</u>, for the temporary relief of mild symptoms of intermittent asthma (ie, wheezing, tightness of chest, and shortness of breath) in adults and children 12 years of age and older.
 - Primatene Mist is not a replacement for prescription asthma treatments.
 - Patients with asthma should be under the care of a health care professional.
- A previous version of OTC Primatene Mist was taken off the market in 2011 because it contained chlorofluorocarbon propellants. This new version of OTC Primatene Mist contains hydrofluoroalkane propellants, which are permitted under current U.S. law.
- Warnings of Primatene Mist include for oral inhalation only; and an asthma alert: because asthma
 may be life threatening, patients should see a doctor if they are not getting better in 20 minutes, get
 worse, need more than 8 inhalations in 24 hours, and/or have more than 2 asthma attacks in a
 week. These may be signs that a patient's asthma is getting worse.
- Primatene Mist should not be used unless a doctor has diagnosed a patient with asthma; or if the
 patient is taking a prescription monoamine oxidase inhibitor (MAOI), or for 2 weeks after stopping
 the MAOI drug.
- Patients should stop use and ask a doctor if: their asthma is getting worse; they have difficulty sleeping; they have a rapid heartbeat; or they have tremors, nervousness, or seizure.
- The recommended dose of Primatene Mist for adults and children ≥ 12 years of age is 1 2 inhalations for each dose.
 - Patients should start with one inhalation and wait at least 1 minute. If not relieved, a second inhalation can be administered.
 - Patients should wait at least 4 hours between doses and should not exceed 8 inhalations in 24 hours.
- Amphastar Pharmaceuticals plans to launch Primatene Mist in early 2019. Primatene Mist will be available as a 0.125 mg epinephrine per spray inhalation aerosol that contains 160 sprays.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.